Table 1.
Clinical information of the patients studied
| Sample | FOXL2 status (*) | Patient age | Tumor stage | Menopausal status |
|---|---|---|---|---|
| 1 | Het | 31 | I | Pre |
| 2 | Het | 48 | Recurrent, metastatic | Pre |
| 3 | Het | 66 | Recurrent, metastatic | Post |
| 4 | Het | 58 | Recurrent, metastatic | Post |
| 5 | Hemi | 50 | Recurrent | Pre |
| 6 | Het | 53 | I | Pre |
| 7 | Het | 54 | I | Pre |
| 8 | Het | 45 | Recurrent | Pre |
| 9 | WT | 71 | Recurrent | Post |
| 10 | Het | 56 | Recurrent | Post |
| 11 | WT | 80 | High grade (1/2) | Post |
| 12 | Het | 50 | Ic | Post |
| 13 | Het | 54 | Recurrent | Post |
| 14 | Het | 79 | 1 | Post |
| COV434 | WT | 27 | Metastatic | Pre |
| KGN | Het | 73 | III, recurrent | Post |
Het heterozygous for the FOXL2 mutation, WT wild-type FOXL2 sequence only, Hemi FOXL2 mutation only (a distinction between homozygous and hemizygous is not possible), see Jamieson et al. [10]